Rituximab: Therapeutic benefit! vitamin R?

Seminars in Hematology

Volumn 47, Issue 2, 2010, Pages 105-106

  Mo, Clifton ^a   Vire, Berengere ^a   Wiestner, Adrian ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYTOTOXIC AGENT; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; HEMATOLOGIC DISEASE; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHEUMATIC DISEASE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; LYMPHOMA; NEUTROPENIA;

EID: 77950319747     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.02.003     Document Type: Editorial

References (6)

1. Dayde D., Ternant D., Ohresser M., et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009, 113:3765-3772.
2. Beum P.V., Kennedy A.D., Williams M.E., Lindorfer M.A., Taylor R.P. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176:2600-2609.
3. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153-2164.
4. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
5. Aue G., Lindorfer M.A., Beum P.V., et al. Fractionated subcutaneous rituximab is well tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
6. Williams M.E., Densmore J.J., Pawluczkowycz A.W., et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006, 177:7435-7443.